Sanofi Terminates Amlitelimab Development in Atopic Dermatitis | iPharmaCenter

Key Regulatory Proposals

Sanofi has officially terminated its clinical development program for amlitelimab, an OX40-ligand targeting monoclonal antibody previously intended for the treatment of moderate-to-severe atopic dermatitis. Following a comprehensive strategic pipeline review, the company has elected to abandon all plans for global regulatory submissions for this indication.

Sanofi is currently initiating a structured wind-down of all ongoing clinical trials, including the phase 3 ESTUARY study (NCT06407934), and is working closely with clinical investigators and regulatory authorities to ensure an orderly transition for patients currently enrolled in these studies.

Despite the discontinuation in dermatology, Sanofi confirmed that development of the asset for celiac disease remains active, with phase 2 trial results projected for the second half of 2026.

Market & Clinical Implications

The decision to halt development stems from internal evaluations concluding that amlitelimab’s clinical performance did not justify further investment. Although data from the ESTUARY long-term extension study indicated that the therapy could maintain clinical response without relapse in patients aged 12 and older, it failed to demonstrate a sufficient therapeutic advantage over current standards of care.

Sanofi intends to release full findings from the amlitelimab development program, including the ESTUARY data, at an upcoming medical conference.

From a market perspective, this move underscores the intensifying competition within the atopic dermatitis therapeutic space.

Amlitelimab, a fully human, non-T cell depleting monoclonal antibody, sought to normalize inflammation by blocking OX40L; however, the lack of a clear efficacy or safety delta against established biologics has rendered the program commercially unviable. The outcome highlights the increasing difficulty for new market entrants to overcome the payer coverage and provider loyalty currently held by entrenched incumbent therapies.